ARK001

About Arkayli Biopharma

Arkayli Biopharma is a privately held, pre-revenue biotech founded in 2021 and based in San Diego, CA. The company is advancing ARK001, a once-daily topical formulation for infantile hemangioma (IH), which is currently in the preclinical stage with the potential to become the first FDA-approved non-systemic treatment for this condition. Arkayli leverages a seasoned leadership team with deep expertise in drug development, dermatology, and commercialization. Its strategy focuses on addressing a clear unmet need in pediatric dermatology through a localized, convenient therapy designed to improve patient and caregiver experiences.

Therapeutic Areas